Literature DB >> 12371145

Mortalin: a potential candidate for biotechnology and biomedicine.

R Wadhwa1, K Taira, S C Kaul.   

Abstract

Mortalin is a novel member of the hsp70 family of proteins that exhibits a different staining pattern in normal and immortal cells. It was also cloned as glucose regulated protein, GRP75 and peptidebinding protein, PBP74. It has been assigned multiple functions ranging from stress response, intracellular trafficking, antigen processing, control of cell proliferation, differentiation and tumorigenesis. The present article compiles and reviews information on multiple sites and functions of mortalin. In view of its upregulation in many tumors and transcriptional inactivation function of p53, its potential use in biotechnology and biomedicine is discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12371145     DOI: 10.14670/HH-17.1173

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  7 in total

1.  Identification of endothelial proteins by MALDI-MS using a compact disc microfluidic system.

Authors:  Daniel Hirschberg; Sam Tryggvason; Magnus Gustafsson; Tomas Bergman; Jesper Swedenborg; Ulf Hedin; Hans Jörnvall
Journal:  Protein J       Date:  2004-05       Impact factor: 2.371

2.  Mortalin-based cytoplasmic sequestration of p53 in a nonmammalian cancer model.

Authors:  Charles Walker; Stefanie Böttger; Ben Low
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

3.  Targeting mortalin using conventional and RNA-helicase-coupled hammerhead ribozymes.

Authors:  Renu Wadhwa; Hiroshi Ando; Hiroaki Kawasaki; Kazunari Taira; Sunil C Kaul
Journal:  EMBO Rep       Date:  2003-06       Impact factor: 8.807

4.  Identification of rTid-1, the rat homologue of the drosophila tumor suppressor l(2)tid gene.

Authors:  Masako Fujita; Yasuo Nagai; Tohru Sawada; Klaus Heese
Journal:  Mol Cell Biochem       Date:  2004-03       Impact factor: 3.396

5.  Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers.

Authors:  Jayarani F Putri; Priyanshu Bhargava; Jaspreet Kaur Dhanjal; Tomoko Yaguchi; Durai Sundar; Sunil C Kaul; Renu Wadhwa
Journal:  J Exp Clin Cancer Res       Date:  2019-12-19

6.  Identification of a new member of Mortaparib class of inhibitors that target mortalin and PARP1.

Authors:  Hazna Noor Meidinna; Seyad Shefrin; Anissa Nofita Sari; Huayue Zhang; Jaspreet Kaur Dhanjal; Sunil C Kaul; Durai Sundar; Renu Wadhwa
Journal:  Front Cell Dev Biol       Date:  2022-09-12

7.  Mortalin deficiency suppresses fibrosis and induces apoptosis in keloid spheroids.

Authors:  Won Jai Lee; Hyo Min Ahn; Youjin Na; Renu Wadhwa; JinWoo Hong; Chae-Ok Yun
Journal:  Sci Rep       Date:  2017-10-11       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.